Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Use Of SB-705498 In The Acute Treatment Of Migraine

Lead Sponsor:

GlaxoSmithKline

Conditions:

Migraine, Acute

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree a...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Healthy subjects suffering from moderate to severe migraine headache with or without aura.
  • Women of child bearing potential must use an effective method of contraception.
  • Have had at least a 1 year history of migraine and the age of onset was prior to 50 years.
  • Suffering 1 to 6 migraine attacks per month for at least the last 3 months and should have at least 48 hours free of headache between migraine attacks.
  • Exclusion criteria:
  • Headache for 15 days/month or greater in any of the three months (90 days) preceding entry into the study.
  • Use of migraine medications (e.g., ergotamine, triptan, opioid, or combination medication) on \>/= 10 days per month on a regular basis for \>/= 3 months.
  • Use of analgesics \>/=15 days per month for \>/=3 months, uses an opiate (except codeine) as first line treatment for migraine.
  • Migraine symptoms do not respond to any of the triptan drugs (e.g., Imitrex, Relpax, Maxalt).
  • Have uncontrolled hypertension or a history/ presence of multiple cardiovascular risk factors such as, but not limited to family history, myocardial infarction, coronary artery disease, vasospastic angina, heart failure, cardiac arrhythmias or history or presence of cerebrovascular disease, including transient ischemic attack, stroke or peripheral arterial disease.
  • History of alcohol, substance or drug abuse within the last year.
  • Participation in a trial with a new chemical entity within 3 months before the start of the study.
  • Participation in any other research trial within 30 days prior to the first dose of current study medication is not permitted.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2006

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    70 Patients enrolled

    Trial Details

    Trial ID

    NCT00269022

    Start Date

    January 1 2006

    Last Update

    May 18 2009

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    GSK Investigational Site

    Randwick, New South Wales, Australia, 2031

    2

    GSK Investigational Site

    Toronto, Ontario, Canada, M1L 4S4

    3

    GSK Investigational Site

    Leiden, Netherlands, 2333 ZA

    4

    GSK Investigational Site

    Cambridge, Cambridgeshire, United Kingdom, CB2 2GG